Elisabeth R. Seyferth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisabeth R. Seyferth has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Abashai A. Woodard
Department of Radiology, University of Pennsylvania Perelman School of Medicine 1
2 shared publications - Bryson William Katona
Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
2 shared publications - Cecilia A. Wright
Department of Radiology, University of Pennsylvania Perelman School of Medicine 1
2 shared publications - Daniel Ackerman
Department of Radiology, University of Pennsylvania Perelman School of Medicine 1
2 shared publications - Daniel M. DePietro
Division of Interventional Radiology, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
2 shared publications - David C. Metz
Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
2 shared publications
Latest Publications
- 27 August 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (9)
PSIP1::TBL1X : a recurrent gene fusion in pancreatic neuroendocrine tumors
Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies, including optical genome mapping (OGM) and whole exome sequencing (WES), to 70 liver metastases of NETs from multiple anatomical primary sites to identify actionable genomic alterations. We detected recurrent fusions involving TBL1X (PSIP1::TBL1X) and BEND2 (CHD7::BEND2 and NEO1::BEND2) by OGM in pancreatic neuroendocrine tumors (pNETs). The expression of the PSIP1::TBL1X fusion was confirmed by PacBio Iso-Seq long-read transcriptome sequencing and nested rtPCR, and fusion protein expression was established by western blotting. Expression of the PSIP1::TBL1X fusion was also assayed in a separate cohort of 31 specimens from 28 pNET cases by rtPCR. Across both cohorts, PSIP1::TBL1X was identified in 11% of pNET patients with available metastatic tissue, but was not detected in primary tumor specimens. All PSIP1::TBL1X fusion isoforms were found to retain early exons of PSIP1 and the complete coding sequence of TBL1X. Consistent with prior reports, BEND2 fusions were associated with high-grade tumors and may represent a clinically useful biomarker for aggressive disease. Notably, TBL1X and BEND2 fusions did not co-occur with ATRX/DAXX mutations, defining a distinct molecular subgroup of pNETs. This study highlights the importance of structural variant profiling in molecular profiling studies and supports a revised view of the role of gene fusions in neuroendocrine malignancies.
- 27 August 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (9)
PSIP1::TBL1X : a recurrent gene fusion in pancreatic neuroendocrine tumors
Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies, including optical genome mapping (OGM) and whole exome sequencing (WES), to 70 liver metastases of NETs from multiple anatomical primary sites to identify actionable genomic alterations. We detected recurrent fusions involving TBL1X (PSIP1::TBL1X) and BEND2 (CHD7::BEND2 and NEO1::BEND2) by OGM in pancreatic neuroendocrine tumors (pNETs). The expression of the PSIP1::TBL1X fusion was confirmed by PacBio Iso-Seq long-read transcriptome sequencing and nested rtPCR, and fusion protein expression was established by western blotting. Expression of the PSIP1::TBL1X fusion was also assayed in a separate cohort of 31 specimens from 28 pNET cases by rtPCR. Across both cohorts, PSIP1::TBL1X was identified in 11% of pNET patients with available metastatic tissue, but was not detected in primary tumor specimens. All PSIP1::TBL1X fusion isoforms were found to retain early exons of PSIP1 and the complete coding sequence of TBL1X. Consistent with prior reports, BEND2 fusions were associated with high-grade tumors and may represent a clinically useful biomarker for aggressive disease. Notably, TBL1X and BEND2 fusions did not co-occur with ATRX/DAXX mutations, defining a distinct molecular subgroup of pNETs. This study highlights the importance of structural variant profiling in molecular profiling studies and supports a revised view of the role of gene fusions in neuroendocrine malignancies.
- Open Access
- 27 March 2026
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (7) , 1391-1399
Long-Term Outcomes of Uterine Artery Embolization for Treatment of Fibroids in Women Under 40: A Retrospective Survey Study at Two Institutions with Median 16-year Follow-up
Purpose: To assess long-term freedom from symptom recurrence and success of entering menopause without hysterectomy for patients younger than 40 years old undergoing uterine fibroid embolization (UFE). Materials and Methods: Women under 40 who underwent UFE from 2001–2012 at two institutions and who participated in a telephone survey in 2024 were included. The survey assessed symptom response to UFE, need for additional procedures, and patient satisfaction with UFE. Results: 976 women underwent UFE; of these, 173 were younger than 40 at the time of UFE, and 80 of 173 (46.2%) participated in the survey. Median age at embolization was 37.2 (range 26.4–39.8) and when surveyed was 52.7 (range 43.1–61.9). 70.0% (56/80) and 18.8% (15/80) of patients reported “a lot” or “a little” symptom improvement, respectively, in the first 6 months after UFE; 11.2% (9/80) reported no change. Of those with improvement, symptoms returned in 57.7% (41/71) with median time to recurrence of 11.0 years (range 0.5–20 years). Freedom from recurrence of symptoms was 68/71 (95.8%) at 1 year, 48/71 (67.6%) at 5 years, and 36/71 (50.7%) at 10 years. Freedom from hysterectomy for recurrent symptoms was 70/71 (98.6%) at 1 year, 60/71 (84.5%) at 5 years, and 51/71 (71.8%) at 10 years. Patient satisfaction with having UFE was a median of 5 on a scale of 1–5 (5 = very satisfied). Conclusion: Women under 40 who undergo UFE are likely to experience return of symptoms before menopause and may require additional procedures, yet they remain highly satisfied with the procedure. Level of Evidence: Level 4, Case Series
- 27 March 2026
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (7) , 1391-1399
Open AccessLong-Term Outcomes of Uterine Artery Embolization for Treatment of Fibroids in Women Under 40: A Retrospective Survey Study at Two Institutions with Median 16-year Follow-up
Purpose: To assess long-term freedom from symptom recurrence and success of entering menopause without hysterectomy for patients younger than 40 years old undergoing uterine fibroid embolization (UFE). Materials and Methods: Women under 40 who underwent UFE from 2001–2012 at two institutions and who participated in a telephone survey in 2024 were included. The survey assessed symptom response to UFE, need for additional procedures, and patient satisfaction with UFE. Results: 976 women underwent UFE; of these, 173 were younger than 40 at the time of UFE, and 80 of 173 (46.2%) participated in the survey. Median age at embolization was 37.2 (range 26.4–39.8) and when surveyed was 52.7 (range 43.1–61.9). 70.0% (56/80) and 18.8% (15/80) of patients reported “a lot” or “a little” symptom improvement, respectively, in the first 6 months after UFE; 11.2% (9/80) reported no change. Of those with improvement, symptoms returned in 57.7% (41/71) with median time to recurrence of 11.0 years (range 0.5–20 years). Freedom from recurrence of symptoms was 68/71 (95.8%) at 1 year, 48/71 (67.6%) at 5 years, and 36/71 (50.7%) at 10 years. Freedom from hysterectomy for recurrent symptoms was 70/71 (98.6%) at 1 year, 60/71 (84.5%) at 5 years, and 51/71 (71.8%) at 10 years. Patient satisfaction with having UFE was a median of 5 on a scale of 1–5 (5 = very satisfied). Conclusion: Women under 40 who undergo UFE are likely to experience return of symptoms before menopause and may require additional procedures, yet they remain highly satisfied with the procedure. Level of Evidence: Level 4, Case Series
- Open Access
Optical genome mapping identifies a novel PSIP1::TBL1X fusion in metastatic pancreatic neuroendocrine tumors
Background and aims Effective treatment of metastatic neuroendocrine tumors is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies to identify genomic alterations that could lead to actionable drug targets and biomarkers. Methods Optical genome mapping (OGM) and whole exome sequencing (WES) was performed on 70 liver metastases of neuroendocrine tumors from multiple anatomical primary sites. PacBio IsoSeq long read sequencing and western blotting was used to confirm fusion gene expression. Findings were validated by rtPCR and western blotting on a separate cohort of 17 resection specimens from 14 pNET cases. Results Somatic variant calling from OGM data detected recurrent fusions involving TBL1X ( PSIP1::TBL1X ) and BEND2 ( CHD7::BEND2 and NEO1::BEND2 ) in pancreatic neuroendocrine tumors (pNETs). BEND2 fusions were associated with high grade tumors, as previously described. The novel PSIP1::TBL1X fusion was confirmed to result in fusion transcript expression by both long-read sequencing and nested rtPCR. Presence of the PSIP1::TBL1X fusion transcript was also confirmed in a second cohort of pNET resection specimens and fusion protein expression was established by western blotting. Both TBL1X and BEND2 fusions are mutually exclusive with ATRX/DAXX mutations. Conclusion This study underscores the importance of structural variants, including fusion genes as both prognostic biomarkers and potential therapeutic targets, especially in ATRX/DAXX negative pNETs. BEND2 fusion positivity may be a clinically useful biomarker for aggressive disease. As all TBL1X fusion isoforms contain the entire TBL1X coding sequence, TBL1X inhibition could be explored as a novel treatment for TBL1X fusion positive pNETs.
Open AccessOptical genome mapping identifies a novel PSIP1::TBL1X fusion in metastatic pancreatic neuroendocrine tumors
Background and aims Effective treatment of metastatic neuroendocrine tumors is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies to identify genomic alterations that could lead to actionable drug targets and biomarkers. Methods Optical genome mapping (OGM) and whole exome sequencing (WES) was performed on 70 liver metastases of neuroendocrine tumors from multiple anatomical primary sites. PacBio IsoSeq long read sequencing and western blotting was used to confirm fusion gene expression. Findings were validated by rtPCR and western blotting on a separate cohort of 17 resection specimens from 14 pNET cases. Results Somatic variant calling from OGM data detected recurrent fusions involving TBL1X ( PSIP1::TBL1X ) and BEND2 ( CHD7::BEND2 and NEO1::BEND2 ) in pancreatic neuroendocrine tumors (pNETs). BEND2 fusions were associated with high grade tumors, as previously described. The novel PSIP1::TBL1X fusion was confirmed to result in fusion transcript expression by both long-read sequencing and nested rtPCR. Presence of the PSIP1::TBL1X fusion transcript was also confirmed in a second cohort of pNET resection specimens and fusion protein expression was established by western blotting. Both TBL1X and BEND2 fusions are mutually exclusive with ATRX/DAXX mutations. Conclusion This study underscores the importance of structural variants, including fusion genes as both prognostic biomarkers and potential therapeutic targets, especially in ATRX/DAXX negative pNETs. BEND2 fusion positivity may be a clinically useful biomarker for aggressive disease. As all TBL1X fusion isoforms contain the entire TBL1X coding sequence, TBL1X inhibition could be explored as a novel treatment for TBL1X fusion positive pNETs.
- Open Access
- 12 November 2025
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 32 (1) , 119-124
Factors affecting the difficulty of transurethral double J stent removal in patients with renal transplants
Factors affecting the difficulty of transurethral double J stent removal in patients with renal transplants - Diagnostic and Interventional Radiology
- 12 November 2025
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 32 (1) , 119-124
Open AccessFactors affecting the difficulty of transurethral double J stent removal in patients with renal transplants
Factors affecting the difficulty of transurethral double J stent removal in patients with renal transplants - Diagnostic and Interventional Radiology
- Open Access
- 18 July 2024
- Published by Springer Nature in Research Square
Association between Statin Intensity and Femoropopliteal Stent Primary Patency in Peripheral Arterial Disease
Background. Statins are widely used in coronary and peripheral arterial disease, but their impact on patency of stents placed for peripheral arterial disease is not well-studied. The purpose of this study was to evaluate femoropopliteal stent primary patency according to statin intensity at the time of stent placement and compare this effect to other covariates that may influence stent patency. Materials and Methods. A retrospective review identified 278 discrete femoropopliteal stent constructs placed in 216 patients over a 10-year period; Rutherford categories were 2 (3.6%), 3 (12.9%), 4 (21.2%), 5 (49.6%), and 6 (12.6%). Stent locations were common femoral (1.8%), common femoral/superficial femoral (0.7%), superficial femoral (50.7%), superficial femoral/popliteal (32.7%) and popliteal (14.0%) arteries; 63.3% of stents were paclitaxel-eluting. Primary patency of each stent construct was determined with duplex ultrasound, angiography, or computed tomographic angiography. Greater than 50% restenosis or stent occlusion was considered loss of patency. Cox proportional hazard and Kaplan-Meier modeling were used to assess the effect of statin use and additional covariates on stent patency. Results. Patients on any statin at the time of stent placement were half as likely to undergo loss of primary unassisted patency as patients on no statin therapy (hazard ratio, 0.53; 95% confidence interval, 0.19–0.87; P = .004). Moderate/high intensity statin therapy conferred 17 additional months of median stent patency compared to the no statin group. Antiplatelet therapy, anticoagulant therapy, drug-eluting stents (versus bare metal or covered stents), and Rutherford class were not predictive of stent patency (P = 0.52, 0.85, 0.58, and 0.82, respectively). Conclusion. Use of statin therapy at the time of femoropopliteal stent placement was the most predictive examined variable influencing primary unassisted patency.
- 18 July 2024
- Published by Springer Nature in Research Square
Open AccessAssociation between Statin Intensity and Femoropopliteal Stent Primary Patency in Peripheral Arterial Disease
Background. Statins are widely used in coronary and peripheral arterial disease, but their impact on patency of stents placed for peripheral arterial disease is not well-studied. The purpose of this study was to evaluate femoropopliteal stent primary patency according to statin intensity at the time of stent placement and compare this effect to other covariates that may influence stent patency. Materials and Methods. A retrospective review identified 278 discrete femoropopliteal stent constructs placed in 216 patients over a 10-year period; Rutherford categories were 2 (3.6%), 3 (12.9%), 4 (21.2%), 5 (49.6%), and 6 (12.6%). Stent locations were common femoral (1.8%), common femoral/superficial femoral (0.7%), superficial femoral (50.7%), superficial femoral/popliteal (32.7%) and popliteal (14.0%) arteries; 63.3% of stents were paclitaxel-eluting. Primary patency of each stent construct was determined with duplex ultrasound, angiography, or computed tomographic angiography. Greater than 50% restenosis or stent occlusion was considered loss of patency. Cox proportional hazard and Kaplan-Meier modeling were used to assess the effect of statin use and additional covariates on stent patency. Results. Patients on any statin at the time of stent placement were half as likely to undergo loss of primary unassisted patency as patients on no statin therapy (hazard ratio, 0.53; 95% confidence interval, 0.19–0.87; P = .004). Moderate/high intensity statin therapy conferred 17 additional months of median stent patency compared to the no statin group. Antiplatelet therapy, anticoagulant therapy, drug-eluting stents (versus bare metal or covered stents), and Rutherford class were not predictive of stent patency (P = 0.52, 0.85, 0.58, and 0.82, respectively). Conclusion. Use of statin therapy at the time of femoropopliteal stent placement was the most predictive examined variable influencing primary unassisted patency.
- 20 December 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (4) , 600-606
Intranodal Glue Embolization for Postoperative Lymphatic Leaks in the Groin and Pelvis: Comparison with Sclerotherapy
- 20 December 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (4) , 600-606
Intranodal Glue Embolization for Postoperative Lymphatic Leaks in the Groin and Pelvis: Comparison with Sclerotherapy
- 1 March 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 33 (3) , 286-294
Safety Profile of Particle Embolization for Treatment of Acute Lower Gastrointestinal Bleeding
- 1 March 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 33 (3) , 286-294
Safety Profile of Particle Embolization for Treatment of Acute Lower Gastrointestinal Bleeding